Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Relay Therapeutics Inc
(NQ:
RLAY
)
7.600
-0.020 (-0.26%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Relay Therapeutics Inc
< Previous
1
2
Next >
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
September 10, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Proposed Public Offering of Common Stock
September 09, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
September 09, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
September 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
July 30, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
June 06, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
June 05, 2024
Initial triplet combination of RLY-2608 + atirmociclib + fulvestrant to be evaluated in patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; initiation planned by end of 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 13, 2024
Company to disclose new programs from existing unnamed pre-clinical pipeline
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
Approximately $750 million in cash, cash equivalents and investments at end of Q1 2024, expected to fund operations into second half of 2026
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
April 25, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Upcoming Investor Conferences
April 11, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
February 26, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
February 22, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
February 15, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces $30 Million Private Placement Financing
January 08, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Unlocking AI investment opportunities in healthcare
November 16, 2023
AI is revolutionizing healthcare by improving diagnosis and accelerating drug discovery. An often-overlooked sector with a wealth of AI opportunities.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Exposures
Artificial Intelligence
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
November 07, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 02, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
October 26, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
October 12, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 18, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 08, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
August 01, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END
Via
FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
May 25, 2023
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
May 24, 2023
From
Relay Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit